| Identification | Back Directory | [Name]
PF-06650833 | [CAS]
1817626-54-2 | [Synonyms]
CS-2457
PF06650883
PF-06650833
PF06650833;PF 06650833
PF06650833 >=98% (HPLC)
1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide
1-[[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxo-2-pyrrolidinyl]methoxy]-7-methoxy-6-isoquinolinecarboxamide
6-Isoquinolinecarboxamide,1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxo-2-pyrrolidinyl)methoxy)-7-methoxy- | [Molecular Formula]
C18H20FN3O4 | [MDL Number]
MFCD30343869 | [MOL File]
1817626-54-2.mol | [Molecular Weight]
361.37 |
| Chemical Properties | Back Directory | [Boiling point ]
621.0±55.0 °C(Predicted) | [density ]
1.34±0.1 g/cm3(Predicted) | [storage temp. ]
room temp | [solubility ]
DMSO : ≥ 33 mg/mL (91.32 mM) | [form ]
powder | [pka]
13.44±0.70(Predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Uses]
Zimlovisertib (PF-06650833) is a potent, selective and orally active inhibitor of interleukin-1 receptor associated kinase 4 (IRAK4) with IC50s of 0.2 and 2.4 nM in the cell and PBMC assay, respectively. Zimlovisertib is used to treat diseases such as rheumatoid arthritis, lupus, and lymphomas[1][2]. | [Biochem/physiol Actions]
PF06650833 has been studied for its use in the treatment of Waldenstrom macroglobulinemia, indicated by overproduction of IgM (immunoglobulin M)-producing lymphoplasmacytic cells. | [in vivo]
Zimlovisertib (0.3-30 mg/kg; oral administration; for 2.5 hours; male Sprague-Dawley rats) treatment significantly inhibits LPS-induced TNF-α in a dose dependent manner. Mean exposures of Zimlovisertib in plasma are 2.1 nM, 7.7 nM, 19 nM and 150 nM free, respectively, at 2.5 hours after oral administration of Zimlovisertib at 0.3, 1, 3, and 30 mg/kg. The fraction unbound in rat plasma of Zimlovisertib is 0.3[1]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.1 mg/kg, 1 mg/kg, 3 mg/kg, 30 mg/kg | | Administration: | Oral administration; for 2.5 hours | | Result: | Significantly inhibited LPS-induced TNF-α in a dose dependent manner.
|
| [IC 50]
IRAK4: .2 nM (IC50) | [storage]
Store at -20°C | [References]
[1] Lee KL, et al. Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design. J Med Chem. 2017 Jul 13;60(13):5521-5542. DOI:10.1021/acs.jmedchem.7b00231
[2] Seganish WM. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015). Expert Opin Ther Pat. 2016 Aug;26(8):917-32. DOI:10.1080/13543776.2016.1202926 |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|